Selective laser trabeculoplasty in steroid-induced and uveitic glaucoma.

Can J Ophthalmol

Department of Ophthalmology, Mayo Clinic, Rochester, Minn.. Electronic address:

Published: August 2022

Objective: To compare primary selective laser trabeculoplasty (SLT) response in uveitic, steroid-induced, primary open-angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEX).

Design: Single-centre retrospective case-control study.

Participants: Patients with uveitic glaucoma, steroid-induced glaucoma, POAG, or PEX who had their first SLT.

Methods: Eyes with POAG or PEX were in control groups. Eyes with steroid-induced or uveitic glaucoma were in experimental groups. Change in intraocular pressure from baseline, treatment failure, complication rates, and medication use were compared using rank-sum and log-rank tests.

Results: Six-hundred and eight eyes of 433 patients were enrolled. Steroid-induced glaucoma eyes had higher mean baseline pressure and a decrease in pressure at 3-8 weeks (27.6-17.4 mm Hg) than those with PEX (21.7-16.5 mm Hg; p < 0.001) or POAG (18.6-14.9 mm Hg; p ≤ 0.025). Failure rates after 2 years were lower in steroid-induced glaucoma (54%) than in PEX (84%; p = 0.01) or POAG (84%; p = 0.005). This survival benefit persisted when excluding patients with changes to their steroid dosing (p ≤ 0.03) but showed mixed results when compared with patients with a baseline pressure of 25mm Hg or greater (p = 0.020 vs PEX; p = 0.67 vs POAG). At 18 months, the steroid-induced group decreased ocular hypotensive medication use (3.5-1.9; p = 0.005); the uveitic group increased medication use (2.7-3.5; p = 0.02).

Conclusions: SLT is an effective treatment for steroid-induced glaucoma, with greater response and a lower failure rate than in PEX and primary POAG, although high baseline intraocular pressure may be a confounder. Judicious use of SLT can be considered in uveitic glaucoma.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcjo.2021.05.006DOI Listing

Publication Analysis

Top Keywords

uveitic glaucoma
16
steroid-induced glaucoma
16
glaucoma
10
selective laser
8
laser trabeculoplasty
8
steroid-induced
8
steroid-induced uveitic
8
glaucoma poag
8
poag pex
8
intraocular pressure
8

Similar Publications

Introduction: To investigate 5-year outcomes on intraocular pressure (IOP) and safety of micropulse transscleral cyclophotocoagulation (TSCPC) in patients with glaucoma.

Methods: Patients with mild to advanced glaucoma who underwent a standardized micropulse TSCPC procedure at the University Eye Clinic Maastricht from November 2016 to February 2019 were included.

Results: A total of 165 eyes were included, with outcomes for 112 eyes available after 5-year follow-up.

View Article and Find Full Text PDF

Sarcoidosis is a systemic granulomatous disease with variable ocular involvement. The most common ocular manifestation is uveitis, which can have potentially sight threatening complications such as glaucoma. We present the case of a man in his 30s with sarcoidosis and recurrent anterior uveitis, necessitating surgical intervention to control intraocular pressure and prevent further glaucomatous optic neuropathy progression.

View Article and Find Full Text PDF

Glaucoma drainage devices (GDD) are used for patients with secondary glaucoma, such as uveitic or neovascular glaucoma, which is uncontrolled under local therapy. They are also used in patients with conjunctival scarring, for example after a previous vitrectomy or after unsuccessful previous glaucoma surgery, such as trabeculectomy. They are also a treatment option for congenital glaucoma, aphakic glaucoma or for the treatment of iridocorneoendothelial syndromes.

View Article and Find Full Text PDF

Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.

Methods: This study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (≥20% IOP reduction, target IOP of 6-21 mmHg).

View Article and Find Full Text PDF

Background/objectives: Evaluate the mid-term outcomes of the PAUL Glaucoma Implant (PGI) in the management of uveitic glaucoma.

Subjects/methods: This was a single-centre, multi-surgeon, retrospective analysis of 50 consecutive cases of PGI for uveitic glaucoma performed between April 2019 and August 2021. Primary outcomes include: complete and qualified success (IOP ≥5 mmHg to ≤21 mmHg with ≥20% IOP reduction) or failure (IOP exceeding the success criteria, additional glaucoma procedures, no perception of light vision).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!